Eye disease patients may want to see more green

As details started leaking out Wednesday from a much-anticipated head-to-head trial of two Genentech Inc. drugs in a potentially blinding eye disease, the folks at Regeneron Pharmaceuticals Inc. were wondering what it all means.That could be decided by patients with age-related macular degeneration who may want to see more of one thing: green in their wallets.